Combinations of succinate-consuming microbiomes

Abstract

The present invention provides combinations of microbial flora selected from the group consisting of Phascolactobacterium faecium, Phascolactobacterium succinatus, Dialister succinatus, Dialister propionysifaciens, Bifidobacterium bifidum, and Lactobacillus intestinalis for use in succinate consumption, processes for producing such combinations, their compositions, and uses.

Claims

1. Phascolarctobacterium faecium, Phascolarctobacterium succinatutens, Dialister succinatutens, Dialister propionicifaciens, Bifidobacterium bifidum, and Lactobacillus intestinalis A combination of succinate-consuming microbiota selected from the group consisting of intestinalis, wherein the ratio of succinate-consuming microbiota is 1:1:1:1:1:1 or 2:4:2:4:2:4 or 4:2:4:2:4:

2.

2. Phascolarctobacterium faecium has a density of 1 x 10⁻⁶. ５ ~1 x 10 １０ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

3. Phascolarctobacterium succinatutens, 1 x 10 ５ ~1 x 10 １０ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

4. Dialister succinatutens is present at 1×10 ５ to 1×10 １０ CFU / ml, preferably in the range of 1×10 ７ to 1×10 ８ CFU / ml, the combination of succinate-consuming microbiota according to claim 1.

5. Dialister propionicifaciens, 1 x 10 ５ ~1 x 10 １０ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

6. Bifidobacterium bifidum, 1 x 10 ５ ~1 x 10 １０ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

7. Lactobacillus intestinalis, 1 x 10 ５ ~1 x 10 １０ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

8. The microbial community is 1 x 10 ５ ~1 x 10 １０ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

9. The succinate-consuming microbiome combination according to claim 1, wherein the microbiome exists in the form of spores, in vitro cultures, L-dried cultures, or freeze-dried microbial cell powder.

10. In addition, the combination of succinate-consuming microbial flora according to claim 1, comprising an endosymbiotic microbial consortium or an extrinsic microbial consortium, or a combination of an endosymbiotic or extrinsic microbial consortium.

11. The succinate-consuming microbial community combination according to claim 1, wherein the internal symbiotic microbial consortium is selected from the group including the phylum Firmicutes, phylum Bacteroidetes, phylum Actinobacteria, phylum Proteobacteria, phylum Fusobacteria, and phylum Verrucomicrobia.

12. The succinate-consuming microbial community combination according to claim 1, wherein the external symbiotic microbial consortium is selected from the group including the phylum Firmicutes, phylum Bacteroidetes, phylum Actinobacteria, phylum Proteobacteria, phylum Fusobacteria, and the genus Verrucomicrobia, genus Malassezia, and family Arthordermataceae.

13. The Endosymbiotic Microorganism Consortium, 1 x 10 ５ ~1 x 10 ９ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

14. The external symbiotic microorganism consortium, 1 x 10 ５ ~1 x 10 ９ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

15. In addition, the combination of succinate-consuming microbial flora according to claim 1, comprising a fungal flora or a viral flora, or a combination of a fungal flora or a viral flora.

16. The fungal community includes Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Candida krusei, Candida lusitaniae, Saccharomyces cerevisiae, Penicillium commune, and Aspergillus versicolor. A combination of succinate-consuming microbiota according to claim 1, selected from the group including versicolor, Cryptococcus, Malassezia globosa, Malassezia restricta, Malassezia pachydermatis, Cladosporium herbarum, Galactomyces geotrichum, Devariomyces hansenii, and Trichosporon.

17. The succinate-consuming microbiome combination according to claim 1, wherein the viral flora is selected from the group including human endogenous retroviruses (HERV), intestinal bacteriophages, lysogenic phages, bactericidal phages, and intestinal bacterial phages.

18. The succinate-consuming microbiome combination according to claim 1, wherein the intestinal bacteriophage is selected from the group including the orders caudavirales, alteromonales, and clostridiales.

19. The succinate-consuming microbiome combination according to claim 1, wherein the phage is selected from acetobutyricum or retroviridae.

20. The succinate-consuming microbiome combination according to claim 1, wherein the phage infects any of the following: Escherichia coli, Lactobacillus, Bacteroides uniformis, or Bacteroides thetaiotaomicron, or a combination thereof.

21. The fungal community is 1 x 10 ５ ~1 x 10 ９ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

22. The viral flora is 1 x 10 ５ ~1 x 10 ９ CFU / ml, preferably 1 × 10 ７ ~1 x 10 ８ A combination of succinate-consuming microbiomes according to claim 1, wherein the CFU / ml range is specified.

23. A composition comprising the succinate-consuming microbiome combination described in claim 1, together with a pharmaceutically acceptable excipient which may be selected from the group comprising microcrystalline cellulose, mannitol, starch, maltodextrin, and dextrin produced from a non-GM source.

24. The composition according to claim 23, comprising a combination of microbiomes present in a pharmaceutically acceptable carrier or matrix, which may be selected from the group comprising kefiran, guar gum, duck foot gelatin (DFG), dextrin, polydextrose, sago starch, pectin, chitosan, chondroitin sulfate, dextran, cyclodextrin, insulin, xanthan gum, amylose, arginate, shellac, locust bean gum, methacrylic acid, methacrylic acid / acrylic acid ester, polyvinyl acetate phthalate, hydroxypropyl ethylcellulose phthalate, cellulose acetate trimellitate, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), and hydroxypropyl methylcellulose phthalate (HPMCP), azo-containing polymers, and polyesters.

25. The composition according to claim 23, comprising an azo-containing polymer that can be selected from the group comprising azo-containing polyurethane, azopolymer hydrogel, styrene copolymer, and 2-hydroxyethyl methacrylate (HEMA) crosslinked with divinylazobenzene (DVAB).

26. The composition according to claim 23, comprising a polyester which may be selected from the group comprising poly-D L-lactic acid-co-glycolic acid (PLGA), polyacrylamide, and polyvinyl alcohol (PVA).

27. The composition according to claim 23, comprising a combination of microbiomes together with at least one indigestible oligosaccharide selected from the group consisting of fructooligosaccharides (FOS), pectin or pectin polysaccharides, mannan, pentosan, β-glucan, arabinan or galactan, human milk oligosaccharides (HMO), glucooligosaccharides, xylooligosaccharides, galactooligosaccharides, arabinoxylan, arabinogalactan, galactomannan, polydextrose, oligofructose, inulin, and mixtures or derivatives thereof.

28. The combination of microbiomes includes Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus salivarius, Lactobacillus intestinalis, Lactobacillus brevis, and Lactobacillus reichmani. The composition according to claim 23, comprising at least one Lactobacillus species selected from the group including Lactobacillus leishmanii, Lactobacillus plantarum, and Lactobacillus cellobiosus.

29. The composition according to claim 23, wherein the combination is encapsulated in microcapsules by spray drying, freeze drying, foam drying, or fluidized bed drying.

30. The composition according to claim 23, formulated for oral, intradermal, intratumor, transdermal, parenteral, intramuscular, intrathecal, topical, intravaginal, intravesical, intracisional, or intrarectal administration.

31. The composition according to claim 23, which is in the form of a solid, semi-solid, freeze-dried powder, liquid dosage form, or aerosol.

32. The composition according to claim 23, comprising a combination of pharmaceutically acceptable microbiomes present in a carrier or matrix, in the form of tablets, capsules, granules, drops, sachets, liquid suspensions, emulsions, chewable tablets, and enteric-coated capsules.

33. A composition comprising the succinate-consuming microbiome combination according to claim 23, for use in reducing succinate, and for all diseases associated with succinate, including microbial dysbiosis selected from the group including obesity, cardiovascular disease (CVD), diabetes, non-alcoholic fatty liver disease (NAFLD), typhoid and paratyphoid, autoimmune and inflammatory diseases, psoriasis, fibrosis (liver and lung), cancer, intracellular infection; Alzheimer's disease, Parkinson's disease, Huntington's disease, and leaky gut associated with other neurological disorders.

Images